Evidence map›Paper›PMID 32451933›Full record

ArticleInternal and emergency medicine2021

Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism.

Gualtiero Palareti, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Angelo A Bignamini, Corrado Lodigiani, Alberto Tosetto, Lorenza Bertù, Vittorio Pengo, Sophie Testa and 4 more

Open access · hybridAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal and emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Heterologous production of chondroitin.Biotechnology reports (Amsterdam, Netherlands) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Gualtiero PalaretiArianna Anticoagulazione" Foundation, Via Paolo Fabbri 1/3, 40138, Bologna, Italy. gualtiero.palareti@unibo.it.ORCID http://orcid.org/0000-0002-4327-9561
Cristina LegnaniArianna Anticoagulazione" Foundation, Via Paolo Fabbri 1/3, 40138, Bologna, Italy.
Emilia AntonucciArianna Anticoagulazione" Foundation, Via Paolo Fabbri 1/3, 40138, Bologna, Italy.
Serena ZorziArianna Anticoagulazione" Foundation, Via Paolo Fabbri 1/3, 40138, Bologna, Italy.
Angelo A BignaminiDepartment of Pharmaceutical Sciences, School of Specialization in Hospital Pharmacy, University of Milan, Milan, Italy.
Corrado LodigianiThrombosis and Hemorrhagic Diseases Unit, Humanitas Research Hospital and Humanitas University, Rozzano (Milan), Italy.
Alberto TosettoDivisione Di Ematologia, Centro Malattie Emorragiche E Trombotiche, AULSS8 Berica, Vicenza, Italy.
Lorenza BertùCentro Di Ricerca Sulle Malattie Tromboemboliche E Le Terapie Antitrombotiche, Università Degli Studi dell'Insubria, Varese, Italy.
Vittorio PengoThrombosis Research Laboratory, Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Sophie TestaDepartment of Laboratory Medicine, Haemostasis and Thrombosis Center, AO Istituti Ospitalieri, Cremona, Italy.
Walter AgenoDipartimento Di Medicina E Chirurgia, Università Degli Studi Dell'Insubria, Varese, Italy.
Domenico PriscoDMSC Università Di Firenze, SOD Medicina Interna Interdisciplinare, AOU Careggi, Florence, Italy.
Paolo PrandoniArianna Anticoagulazione" Foundation, Via Paolo Fabbri 1/3, 40138, Bologna, Italy.
Daniela PoliCentro Trombosi, Azienda Ospedaliera Careggi, Florence, Italy.
ANT Foundation Italy Onlus · ITUniversity of Insubria · ITAzienda Ospedaliero-Universitaria Careggi · ITHumanitas University · ITIstituti Ospitalieri di Cremona · ITUniversity of Milan · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

How to prevent recurrences after a first venous thromboembolic (VTE) event in elderly patients is still an open issue, especially because of the high bleeding risk of anticoagulation in these patients. The placebo-controlled "Jason" study aims at assessing the efficacy and safety for secondary VTE prevention in elderly patients of oral Sulodexide (Vessel

Indexed as

Research DesignSecondary PreventionAgedAnticoagulantsDouble-Blind MethodFemaleGlycosaminoglycansHumansMalePlacebosRandomized Controlled Trials as TopicVenous ThromboembolismAnticoagulantsglucuronyl glucosamine glycan sulfateGlycosaminoglycansPlacebosElderlyExtensionRecurrenceSulodexideVenous thromboembolism

Identifiers

PMID32451933
PMCPMC7952285
OpenAlexW3027533367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.